Literature DB >> 16239911

Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations.

M Griffiths, J Mason, M Rindl, S Akiki, D McMullan, V Stinton, H Powell, A Curtis, N Bown, C Craddock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16239911     DOI： 10.1038/sj.leu.2403988

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

2.  Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

Authors:  J C T Loke; S Akiki; J Borrow; J Ewing; S W Bokhari; D Chandra; J Arrazi; P Hazlewood; K Arthur; J Walsh; Y Membwange; F A Wandroo; A Watts; A Borg; K Brock; P Ferguson; C Craddock; M Griffiths; M Raghavan
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 3.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

4.  FLT3/ITD AML and the law of unintended consequences.

Authors:  Mark Levis
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

5.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

Authors:  Andrew J Dunbar; Lukasz P Gondek; Christine L O'Keefe; Hideki Makishima; Manjot S Rataul; Hadrian Szpurka; Mikkael A Sekeres; Xiao Fei Wang; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

Authors:  Ramon V Tiu; Lukasz P Gondek; Christine L O'Keefe; Jungwon Huh; Mikkael A Sekeres; Paul Elson; Michael A McDevitt; Xiao Fei Wang; Mark J Levis; Judith E Karp; Anjali S Advani; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

7.  Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer.

Authors:  Musaffe Tuna; Marcel Smid; Dakai Zhu; John W M Martens; Christopher I Amos
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Authors:  Anna M Jankowska; Hadrian Szpurka; Ramon V Tiu; Hideki Makishima; Manuel Afable; Jungwon Huh; Christine L O'Keefe; Rebecca Ganetzky; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

9.  Acquired copy number alterations in adult acute myeloid leukemia genomes.

Authors:  Matthew J Walter; Jacqueline E Payton; Rhonda E Ries; William D Shannon; Hrishikesh Deshmukh; Yu Zhao; Jack Baty; Sharon Heath; Peter Westervelt; Mark A Watson; Michael H Tomasson; Rakesh Nagarajan; Brian P O'Gara; Clara D Bloomfield; Krzysztof Mrózek; Rebecca R Selzer; Todd A Richmond; Jacob Kitzman; Joel Geoghegan; Peggy S Eis; Rachel Maupin; Robert S Fulton; Michael McLellan; Richard K Wilson; Elaine R Mardis; Daniel C Link; Timothy A Graubert; John F DiPersio; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

10.  Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML.

Authors:  D L Stirewalt; E L Pogosova-Agadjanyan; K Tsuchiya; J Joaquin; S Meshinchi
Journal:  Blood Cancer J       Date:  2014-05-02       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.